Evolution and Recent Developments of the Gaseous Photon Detectors Technologies

The evolution and the present status of the gaseous photon detectors technologies are reviewed. The most recent developments in several branches of the field are described, in particular the installation and commissioning of the first large area MPGD-based detectors of single photons on COMPASS RICH-1. Investigation of novel detector architectures, different materials and various applications are reported, and the quest for visible light gaseous photon detectors is discussed. The progress on the use of gaseous photon detector related techniques in the field of cryogenic applications and gaseous or liquid scintillation imaging are presented.Comment: NDIP 2017 Proceedings, review, submitted to Nuc. Inst. Methods

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We designed a single-arm prospective, multicentre, open-label phase II study to evaluate the combination of erlotinib (100 mg/d, orally) and weekly FDR-Gem (1000 mg/m2, infused at 10 mg/m2per minute) in a population of previously untreated patients with locally advanced, inoperable, or metastatic pancreatic cancer. Primary endpoint was the rate of progression-free survival at 6 mo (PFS-6); secondary endpoints were overall response rate (ORR), response duration, tolerability, overall survival (OS), and clinical benefit. Treatment was not considered to be of further interest if the PFS-6 was < 20% (p0 = 20%), while a PFS-6 > 40% would be of considerable interest (p1 = 40%); with a 5% rejection error (α = 5%) and a power of 80%, 35 fully evaluable patients with metastatic disease were required to be enrolled in order to complete the study. Analysis of prognostic factors for survival was also carried out. RESULTS: From May 2007 to September 2009, 46 patients were enrolled (male/female: 25/21; median age: 64 years; median baseline carbohydrate antigen 19-9 (CA 19-9): 897 U/mL; locally advanced/metastatic disease: 5/41). PFS-6 and median PFS were 30.4% and 14 wk (95%CI: 10-19), respectively; 1-year and median OS were 20.2% and 26 wk (95%CI: 8-43). Five patients achieved an objective response (ORR: 10.9%, 95%CI: 1.9-19.9); disease control rate was 56.5% (95%CI: 42.2-70.8); clinical benefit rate was 43.5% (95%CI: 29.1-57.8). CA 19-9 serum levels were decreased by > 25% as compared to baseline in 14/23 evaluable patients (63.6%). Treatment was well-tolerated, with skin rash being the most powerful predictor of both longer PFS (P < 0.0001) and OS (P = 0.01) at multivariate analysis (median OS for patients with or without rash: 42 wk vs 15 wk, respectively, Log-rank P = 0.03). Additional predictors of better outcome were: CA 19-9 reduction, female sex (for PFS), and good performance status (for OS). CONCLUSION: Primary study endpoint was not met. However, skin rash strongly predicted erlotinib efficacy, suggesting that a pharmacodynamic-based strategy for patient selection deserves further investigation

Proceedings of the International PrimeNet Workshop

These are the proceedings of the PrimeNet Workshop, held in September 16-18, 2010, at the campus of Instituto Superior T\'ecnico in Lisbon, Portugal. This workshop is part of the activities in the project "Study of Strongly Interacting Matter" (acronym HadronPhysics2), which is an integrating activity of the Seventh Framework Program of EU. This HP2 project contains several activities, one of them being the network PrimeNet having the focus on Meson Physics in Low-Energy QCD. This network is created to exchange information on experimental and theoretical ongoing activities on mainly eta and eta-prime physics at different European accelerator facilities and institutes.Comment: 78 pages; Each talk is represented by an extended abstrac

Recent Advances in the Synthetic and Mechanistic Aspects of the Ruthenium-catalyzed Carbon-heteroatom Bond Forming Reactions of Alkenes and Alkynes

The group’s recent advances in catalytic carbon-to-heteroatom bond forming reactions of alkenes and alkynes are described. For the C–O bond formation reaction, a well-defined bifunctional ruthenium-amido catalyst has been successfully employed for the conjugate addition of alcohols to acrylic compounds. The ruthenium-hydride complex (PCy3)2(CO)RuHCl was found to be a highly effective catalyst for the regioselective alkyne-to-carboxylic acid coupling reaction in yielding synthetically useful enol ester products. Cationic ruthenium-hydride catalyst generated in-situ from (PCy3)2(CO)RuHCl/HBF4·OEt2 was successfully utilized for both the hydroamination and related C–N bond forming reactions of alkenes. For the C–Si bond formation reaction, regio- and stereoselective dehydrosilylation of alkenes and hydrosilylation of alkynes have been developed by using a well-defined ruthenium-hydride catalyst. Scope and mechanistic aspects of these carbon-to-heteroatom bond forming reactions are discussed

Precision Crystal Calorimeters in High Energy Physics: Past, Present and Future

Precision crystal calorimeters traditionally play an important role in high energy physics experiments. In the last two decades, it faces a challenge to maintain its precision in a hostile radiation environment. This paper reviews the performance of crystal calorimeters constructed for high energy physics experiments and the progress achieved in understanding crystal's radiation damage as well as in developing high quality scintillating crystals for particle physics. Potential applications of new generation scintillating crystals of high density and high light yield, such as LSO and LYSO, in particle physics experiments is also discussed

MesonNet 2013 International Workshop. Mini-proceedings

The mini-proceedings of the MesonNet 2013 International Workshop held in Prague from June 17th to 19th, 2013, are presented. MesonNet is a research network within EU HadronPhysics3 project (1/2012 -- 12/2014). The web page of the conference, which contains all talks, can be found at http://ipnp.mff.cuni.cz/mesonnet13Comment: 106 pages, 53 contributions. Mini-proceedings of the MesonNet 2013 International Workshop. Editors: K. Kampf, A. Kupsc, and P. Masjua